Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sobi® will present new data at the 17th European Association of Haemophilia and Allied Disorders conference in Frankfurt from 6-9 February 2024. The studies that will be presented support Sobi's...
Jiangsu Recbio Technology Co., Ltd. announced that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive results in the interim...
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...
Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced Last Patient Last Vi
Company on track to report top line data milestone in 1Q 2024A total of 210 participants have been recruitedMultiple primary endpoints include reduction in agitation and aggression and overall BPD...